Cagrilintide is a long-acting amylin analogue designed to regulate appetite and body-weight by mimicking the physiological actions of amylin, a hormone co-secreted with insulin by pancreatic β-cells. It is engineered for extended receptor engagement, allowing sustained effects on satiety signaling.
Cagrilintide (10 Mg)
Cagrilintide activates amylin receptors (AMYRs) within the central nervous system, particularly in appetite-regulating regions such as the brainstem and hypothalamus. Through this pathway, it:
• Enhances satiety (you feel full sooner)
• Reduces hunger and food intake
• Slows gastric emptying, contributing to prolonged fullness
• Modulates reward-driven eating, decreasing cravings
Unlike incretin therapies, its primary action is amylin-mediated, making it complementary to GLP-1–based agents.
